Testing effectiveness (Phase 2)Not Yet RecruitingNCT05540275
What this trial is testing
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
Who this might be right for
Recurrent Glioblastoma
Henan Provincial People's Hospital 30